A detailed history of Sumitomo Life Insurance CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Sumitomo Life Insurance CO holds 17,205 shares of ABBV stock, worth $2.91 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
17,205
Previous 27,003 36.28%
Holding current value
$2.91 Million
Previous $5.33 Million 42.67%
% of portfolio
0.06%
Previous 0.1%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 23, 2025

SELL
$164.99 - $203.87 $1.62 Million - $2 Million
-9,798 Reduced 36.28%
17,205 $3.06 Million
Q3 2024

Oct 16, 2024

BUY
$163.84 - $199.33 $1.01 Million - $1.23 Million
6,161 Added 29.56%
27,003 $5.33 Million
Q2 2024

Jul 19, 2024

SELL
$154.79 - $180.76 $421,493 - $492,209
-2,723 Reduced 11.56%
20,842 $3.57 Million
Q1 2024

Apr 26, 2024

SELL
$159.82 - $182.1 $143,518 - $163,525
-898 Reduced 3.67%
23,565 $4.29 Million
Q4 2023

Jan 30, 2024

SELL
$137.6 - $154.97 $174,889 - $196,966
-1,271 Reduced 4.94%
24,463 $3.79 Million
Q3 2023

Oct 23, 2023

SELL
$133.59 - $154.65 $45,019 - $52,117
-337 Reduced 1.29%
25,734 $3.84 Million
Q2 2023

Jul 20, 2023

SELL
$132.51 - $164.9 $334,455 - $416,207
-2,524 Reduced 8.83%
26,071 $3.51 Million
Q1 2023

Apr 27, 2023

SELL
$144.61 - $166.54 $30,368 - $34,973
-210 Reduced 0.73%
28,595 $4.56 Million
Q4 2022

Jan 17, 2023

SELL
$138.31 - $165.87 $39,280 - $47,107
-284 Reduced 0.98%
28,805 $4.66 Million
Q3 2022

Oct 31, 2022

SELL
$134.21 - $153.93 $473,895 - $543,526
-3,531 Reduced 10.82%
29,089 $3.9 Million
Q2 2022

Jul 22, 2022

BUY
$137.62 - $174.96 $88,489 - $112,499
643 Added 2.01%
32,620 $5 Million
Q1 2022

Apr 27, 2022

SELL
$131.98 - $163.75 $67,441 - $83,676
-511 Reduced 1.57%
31,977 $5.18 Million
Q4 2021

Feb 04, 2022

SELL
$107.43 - $135.93 $103,025 - $130,356
-959 Reduced 2.87%
32,488 $4.4 Million
Q3 2021

Oct 25, 2021

SELL
$106.4 - $120.78 $150,449 - $170,782
-1,414 Reduced 4.06%
33,447 $3.61 Million
Q2 2021

Jul 20, 2021

SELL
$105.21 - $117.21 $566,976 - $631,644
-5,389 Reduced 13.39%
34,861 $3.93 Million
Q1 2021

Apr 27, 2021

SELL
$102.3 - $112.62 $1.19 Million - $1.31 Million
-11,616 Reduced 22.4%
40,250 $4.36 Million
Q4 2020

Feb 05, 2021

SELL
$80.49 - $108.67 $381,844 - $515,530
-4,744 Reduced 8.38%
51,866 $5.56 Million
Q3 2020

Oct 29, 2020

SELL
$85.91 - $100.83 $404,722 - $475,010
-4,711 Reduced 7.68%
56,610 $4.96 Million
Q2 2020

Jul 22, 2020

BUY
$73.37 - $98.18 $151,288 - $202,447
2,062 Added 3.48%
61,321 $6.02 Million
Q1 2020

May 01, 2020

BUY
$64.5 - $97.79 $63,081 - $95,638
978 Added 1.68%
59,259 $4.52 Million
Q4 2019

Jan 24, 2020

BUY
$72.13 - $90.25 $236,802 - $296,290
3,283 Added 5.97%
58,281 $5.16 Million
Q3 2019

Oct 24, 2019

BUY
$62.98 - $75.72 $271,443 - $326,353
4,310 Added 8.5%
54,998 $4.16 Million
Q2 2019

Jul 26, 2019

BUY
$65.7 - $83.98 $136,261 - $174,174
2,074 Added 4.27%
50,688 $3.69 Million
Q1 2019

Apr 17, 2019

SELL
$77.14 - $90.79 $424,115 - $499,163
-5,498 Reduced 10.16%
48,614 $3.92 Million
Q4 2018

Jan 24, 2019

SELL
$77.85 - $96.01 $224,830 - $277,276
-2,888 Reduced 5.07%
54,112 $4.99 Million
Q3 2018

Oct 18, 2018

SELL
$88.91 - $98.84 $535,327 - $595,115
-6,021 Reduced 9.55%
57,000 $5.39 Million
Q2 2018

Jul 23, 2018

BUY
$89.78 - $106.23 $263,414 - $311,678
2,934 Added 4.88%
63,021 $5.84 Million
Q1 2018

Apr 27, 2018

SELL
$92.01 - $123.21 $499,430 - $668,783
-5,428 Reduced 8.29%
60,087 $5.69 Million
Q4 2017

Feb 01, 2018

BUY
$89.56 - $98.21 $546,495 - $599,277
6,102 Added 10.27%
65,515 $6.34 Million
Q3 2017

Oct 17, 2017

BUY
$69.85 - $89.22 $4.15 Million - $5.3 Million
59,413
59,413 $5.28 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $299B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Sumitomo Life Insurance CO Portfolio

Follow Sumitomo Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Life Insurance CO with notifications on news.